header-logo header-logo

A bitter pill?

28 February 2014 / Sarah Moore
Issue: 7596 / Categories: Features , Regulatory
printer mail-detail

What impact will the new European Medical Device Regulations have on UK medicine, asks Sarah Moore

At the end of last year, after a year of fierce lobbying by patient groups and manufacturers alike, the new European Medical Device Regulations were finally submitted to the European Parliament and Council for debate and member state approval. When implemented, these new regulations will change legislation that has remained largely untouched for over 20 years.

Ongoing, high profile, prosthetic hip and breast implant litigation has played a key role in galvanising this change. However, exactly what impact these proposed regulatory changes will have, both for patient safety and product litigation in the UK remains to be seen.

EUCOMED, the organisation which speaks for European medical device manufacturers, has warned that the new regulations will stifle innovation and slow down the release of novel products into the market. For product liability lawyers, and others dealing with the after-effects of “novel” products, such as the ASR hip prosthesis, this change in pace has the potential at least to better

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Quinn Emanuel Urquhart & Sullivan—Andrew Savage

Quinn Emanuel Urquhart & Sullivan—Andrew Savage

Firm expands London disputes practice with senior partner hire

Druces—Lisa Cardy

Druces—Lisa Cardy

Senior associate promotion strengthens real estate offering

Charles Russell Speechlys—Robert Lundie Smith

Charles Russell Speechlys—Robert Lundie Smith

Leading patent litigator joins intellectual property team

NEWS
The government’s plan to introduce a Single Professional Services Supervisor could erode vital legal-sector expertise, warns Mark Evans, president of the Law Society of England and Wales, in NLJ this week
Writing in NLJ this week, Jonathan Fisher KC of Red Lion Chambers argues that the ‘failure to prevent’ model of corporate criminal responsibility—covering bribery, tax evasion, and fraud—should be embraced, not resisted
Professor Graham Zellick KC argues in NLJ this week that, despite Buckingham Palace’s statement stripping Andrew Mountbatten Windsor of his styles, titles and honours, he remains legally a duke
Writing in NLJ this week, Sophie Ashcroft and Miranda Joseph of Stevens & Bolton dissect the Privy Council’s landmark ruling in Jardine Strategic Ltd v Oasis Investments II Master Fund Ltd (No 2), which abolishes the long-standing 'shareholder rule'
In NLJ this week, Sailesh Mehta and Theo Burges of Red Lion Chambers examine the government’s first-ever 'Afghan leak' super-injunction—used to block reporting of data exposing Afghans who aided UK forces and over 100 British officials. Unlike celebrity privacy cases, this injunction centred on national security. Its use, the authors argue, signals the rise of a vast new body of national security law spanning civil, criminal, and media domains
back-to-top-scroll